Coeptis Therapeutics (NASDAQ:ZSQR) Sees Unusually-High Trading Volume – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares saw unusually-high trading volume on Tuesday . Approximately 58,682 shares changed hands during mid-day trading, a decline of 45% from the previous session’s volume of 107,489 shares.The stock last traded at $13.32 and had previously closed at $12.77.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Coeptis Therapeutics has a consensus rating of “Sell”.

Coeptis Therapeutics Trading Up 4.8%

The firm has a market cap of $801.79 million, a price-to-earnings ratio of -6.19 and a beta of -0.22. The business’s 50 day moving average price is $12.04 and its 200-day moving average price is $12.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last issued its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Investors Weigh In On Coeptis Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. State Street Corp raised its stake in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics during the fourth quarter worth about $259,000. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics during the third quarter worth about $140,000. Finally, Steward Partners Investment Advisory LLC raised its stake in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. Institutional investors and hedge funds own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.